Iñigo González Larreategui

Mr. Iñigo González Larreategui

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
ILIñigo González Larreategui
Iñigo González Larreategui
DCDaniel Capitán-Leo
Daniel Capitán-Leo
LSLaura Soucek
Laura Soucek
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The cooperative interplay between RAS and MYC constitutes a complex and multifaceted phenomenon, profoundly influencing tumor development. Together and individually, these two oncogenes regulate most, if not all, hallmarks of cancer, including cell death escape, replicative immortality, tumor-associated angiogenesis, cell invasion and metastasis, metabolic adaptation, and immune evasion. Due to their frequent alteration and role in tumorigenesis, MYC and RAS emerge as highly appealing targets in cancer therapy. However, due to their complex nature, both oncogenes have been long considered “undruggable” and, until recently, no drugs directly targeting them had reached the clinic. This review aims to shed light on their complex partnership, with special attention to their active collaboration in fostering an immunosuppressive milieu and driving immunotherapeutic resistance in cancer. Within this review, we also present an update on the different inhibitors targeting RAS and MYC currently undergoing clinical trials, along with their clinical outcomes and the different combination strategies being explored to overcome drug resistance. This recent clinical development suggests a paradigm shift in the long-standing belief of RAS and MYC “undruggability”, hinting at a new era in their therapeutic targeting.

Verified
Journal Article
Open access
PDF file
MMMaria Jose Mansilla
Maria Jose Mansilla
ILIñigo González Larreategui
Iñigo González Larreategui
NFNeus Figa-Martín
Neus Figa-Martín
JBJaume Barallat
Jaume Barallat
FFFederico Fondelli
Federico Fondelli
ECEva Mª Martínez Cáceres
Eva Mª Martínez Cáceres
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. To identify molecules and pathways involved in the generation of VitD3-tolDC, we established an easy and fast gene silencing method based on the use of Viromer blue to introduce siRNA into monocytes on day 1 of culture differentiation. The analysis of the effect of CD209 (DC-SIGN) and CD115 (CSF1R) down-modulation on the phenotype and functionality of transfected VitD3-tolDC revealed a partial role of CD115 in their tolerogenicity. Further investigations showed that CSF1R-CSF1 signaling is involved in the induction of cell metabolic reprogramming, triggering glycolysis to produce high amounts of lactate, a novel suppressive mechanism of T cell proliferation, recently found in autologous tolerogenic dendritic cells (ATDCs).

2 March 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MZMariano F Zacarías-Fluck
Mariano F Zacarías-Fluck
TJToni Jauset
Toni Jauset
SMSandra Martínez-Martín
Sandra Martínez-Martín
JKJastrinjan Kaur
Jastrinjan Kaur
SCSílvia Casacuberta-Serra
Sílvia Casacuberta-Serra
LSLaura Soucek
Laura Soucek
The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. Here, we describe how only the lack of the receptor Fzd9, previously identified as a Myc transcriptional target, impairs sustained tumor expansion and β-cell dedifferentiation in a mouse model of Myc-driven insulinoma, allows pancreatic islets to maintain their physiological structure and affects Myc-related global gene expression. Importantly, Wnt signaling inhibition in Fzd9-competent mice largely recapitulates the suppression of proliferation caused by Fzd9 deficiency upon Myc activation. Together, our results indicate that the Wnt signaling receptor Fzd9 is essential for Myc-induced tumorigenesis in pancreatic islets.